Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

ACTION3

  • Home
  •  
  • ACTION3



  • Most Read
  • Latest Comments
  • European regulator accept Dimerix’s Paediatric Investigation Plan to develop DMX-200 for kidney disorders
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • European regulator accept Dimerix’s Paediatric Investigation Plan to develop DMX-200 for kidney disorders
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • European regulator accept Dimerix’s Paediatric Investigation Plan to develop DMX-200 for kidney disorders
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • European regulator accept Dimerix’s Paediatric Investigation Plan to develop DMX-200 for kidney disorders
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • European regulator accept Dimerix’s Paediatric Investigation Plan to develop DMX-200 for kidney disorders
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Mayne Pharma settles shareholder class action for $38M with no admission of guilt
    Mayne Pharma settles shareholder class action for $38M with no admission of guilt
    • News

  • Vita Life Sciences reports sales growth of $4m as it launches in Vietnam
    Vita Life Sciences reports sales growth of $4m as it launches in Vietnam
    • News

  • Firebrick’s nasal hygiene spray launched in the US without FDA approvals
    Firebrick’s nasal hygiene spray launched in the US without FDA approvals
    • News

  • Amplia reports results from initial clinical trials of pancreatic cancer drug
    Amplia reports results from initial clinical trials of pancreatic cancer drug
    • News

  • European regulator accept Dimerix’s Paediatric Investigation Plan to develop DMX-200 for kidney disorders
    • News

    European regulator accept Dimerix’s Paediatric Investigation Plan to develop DMX-200 for kidney disorders

    Biopharmaceutical company Dimerix (ASX: DXB) has won the favour of the Paediatric Committee (PDCO) of the European Medicines Agency (EMA), as the committee has formally accepted Dimerix’s Paediatric Investigation Plan for the development of DMX-200, a potential treatment for kidney disease. The PDCO’s approval comes after a meeting on June 23, 2023, and paves the

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.